Antisense phosphorothioate oligodeoxynucleotide down-regulation of the insulin-like growth factor I receptor in ovarian cancer cells

International Journal of Cancer

Volumn 77, Issue 4, 1998, Pages 567-571

  Müller, Markus ^a   Dietel, Manfred ^a   Turzynski, Andreas ^a   Wiechen, Kai ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; MONOCLONAL ANTIBODY; OLIGODEOXYNUCLEOTIDE PHOSPHOROTHIOATE; SOMATOMEDIN C RECEPTOR;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL PROLIFERATION; FLOW CYTOMETRY; GROWTH INHIBITION; MALIGNANT TRANSFORMATION; NUCLEIC ACID PROBE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR OCCUPANCY; TISSUE SPECIFICITY;

CELL DIVISION; DOWN-REGULATION; FEMALE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; OLIGONUCLEOTIDES, ANTISENSE; OVARIAN NEOPLASMS; RECEPTOR, IGF TYPE 1; RNA, MESSENGER; THIONUCLEOTIDES; TUMOR CELLS, CULTURED;

EID: 2642704208     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19980812)77:4<567::AID-IJC16>3.0.CO;2-3     Document Type: Article

References (18)

1. ARTEAGA, C.L. and OSBORNE, C.K., Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res., 49, 6237-6241 (1989).
2. BASERGA, R., The insulin-like growth factor I receptor: a key to tumor growth? Cancer Res., 55, 249-252 (1995).
3. BERGMANN, U., FUNATOMI, H., YOKOYAMA, M., BEGER, H.G. and KORC, M., Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res., 55, 2007-2011 (1995).
4. BURFEIND, P., CHERNICKY, C.L., RININSLAND, F., ILAN, J. and ILAN, J., Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc. nat. Acad. Sci (Wash.), 93, 7263-7268 (1996).
5. COPPOLA, D., FERBER, A., MIURA, M., D'AMBROSIO, C., RUBIN, R. and BASERGA, R., A functional insulin-like growth factor I receptor is required for the mitogenic and transforming activities of the epidermal growth factor receptor. Mol. cell. Biol., 14, 4588-4595 (1994).
6. FELGNER, J.H., KUMAR, R., SRIDHAR, C.N., WHEELER, C.J., TSAI, Y.J., BORDER, R., RAMSEY, P., MARTIN, M. and FELGNER, P.L., Enhanced gene delivery and mechanism studies with a novel series of cationic lipid formulations. J. biol. Chem., 269, 2550-2561 (1994).
7. GOLDRING, M.B. and GOLDRING, S.R., Cytokines and cell growth control. Eukaryotic Gene Expr., 1, 301-326 (1991).
8. PRAGER, D., LI, H.L., ASA, S. and MELAMED, S., Dominant negative inhibition of tumorigenesis in vivo by human insulin-like growth factor I receptor mutant. Proc. nat. Acad. Sci. (Wash.), 91, 2181-2185 (1994).
9. RESNICOFF, M., COPPOLA, SELL, C., RUBIN, R., FERRONE, S. and BASERGA, R., Growth inhibition of human melanoma cells in nude mice by antisense strategies to the type 1 insulin-like growth factor receptor. Cancer Res., 54, 4848-4850 (1994a).
10. RESNICOFF, M., SELL, C. RUBINI, M., COPPOLA, D., AMBROSE, D., BASERGA, R. and RUBIN, R., Rat glioblastoma cells expressing an antisense RNA to the insulin-like growth factor-1 (IGF-1) receptor are nontumorigenic and induce regression of wild-type tumors. Cancer Res., 54, 2218-2222 (19946).
11. SELL, C., RUBINI, M., RUBIN, R., LIU, J.-P., EFSTRATIADIS, A. and BASERGA, R., Simian virus 40 large tumor antigen is unable to transform mouse embryonic fibroblasts lacking type 1 insulin-like growth factor receptor. Proc. nat. Acad. Sci. (Wash.), 90, 11217-11221 (1993).
12. SHAPIRO, D.N., JONES, B.G., SHAPIRO, L.H., DIAS, P. and HOUGHTON, P.J., Antisense-mediated reduction in insulin-like growth factor-I receptor expression suppresses the malignant phenotype of a human alveolar rhabdomyosarcoma. J. clin. Invest., 94, 1235-1242 (1994).
13. STEIN, C.A. and CHENG, Y.-C., Antisense oligonucleotides as therapeutic agents - is the bullet really magical? Science, 261, 1004-1012 (1993).
14. ULLRICH, A. and 13 OTHERS, Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J., 5, 2503-2512 (1986).
15. VAUGHN, J.P., IGLEHART, J.D., DEMIRDJI, S., DAVIS, P., BABISS, L.E., CARUTHERS, M.H. and MARKS, J.R., Antisense DNA down-regulation of the ERBB2 oncogene measured by a flow cytometric assay. Proc. nat. Acad. Sci. (Wash.), 92, 8338-8342 (1995).
16. WAGNER, R.W., Gene inhibition using antisense oligodeoxynucleotides. Nature (Lond.), 372, 333-335 (1994).
17. YEE, D., MORALES, F.R., HAMILTON, T.C. and VON HOFF, D.D., Expression of insulin-like growth factor I, its binding proteins, and its receptor in ovarian cancer. Cancer Res., 51, 5107-5112 (1991).
18. ZAPF, J., Physiological role of the insulin-like growth factor binding proteins. Europ. J. Endocrinol., 132, 645-654 (1995).